Drugs / Huolingshengji Granules
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04950933 | Jun 2020 → Dec 2021 | amyotrophic lateral sclerosis | Peking University Third Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Huolingshengji Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04950933 ↗ |
| Route | Oral | “1 bag of Huolingshengji Granules each time + 1 tablet of Riluzole tablet simulation agent each time, twice a day, orally;” NCT04950933 ↗ |